Nebraska Methodist Cancer Center

Omaha, Nebraska 68114

0 studies enrolling now · 17 studies all time

What they study most

Breast Cancer, Carcinoma, Chronic Myeloid Leukemia, Extensive-Stage Small Cell Lung Cancer, HER2 Negative Breast Cancer, Intracranial Meningioma, Melanoma, Metastatic Breast Cancer, Metastatic Melanoma, Multiple Myeloma, Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer

Studies at this site

• A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma — Completed
• A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma — Completed
• Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer — Completed
• Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma — Stopped early
• Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy — Completed
• Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer — Completed
• Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer — Completed
• Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer — Completed
• Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site — Completed
• A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer — Completed
• Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib — Completed
• Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC — Completed
• Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer — Completed
• Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma — Completed
• Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma — Stopped early
• Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma — Completed
• Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia — NO_LONGER_AVAILABLE